Insiders / Fust Matthew K

Fust Matthew K

CIK 1397266personinsider
Companies
4
First seen
May 18, 2026
Last activity
Jun 22, 2026

Companies

CompanyRoleShares heldPeak heldTradesLatest
Ultragenyx Pharmaceutical Inc. · RAREDirector33,69633,6962
Atara Biotherapeutics, Inc. · ATRADirector30,18830,1881
Crinetics Pharmaceuticals, Inc. · CRNXDirector28,76128,7612
Neumora Therapeutics, Inc. · NMRADirector80,0001

All securities held

6 positions · latest reported per filing
CompanySecuritySharesAs of
Atara Biotherapeutics, Inc.Common Stock30,188Jun 9, 2026
Crinetics Pharmaceuticals, Inc.Common Stock28,761Jun 18, 2026
Crinetics Pharmaceuticals, Inc.Stock Option (Right to Buy)Derivative9,730Jun 18, 2026
Neumora Therapeutics, Inc.Stock Option (Right to Buy)Derivative80,000May 27, 2026
Ultragenyx Pharmaceutical Inc.Common Stock33,696May 14, 2026
Ultragenyx Pharmaceutical Inc.Stock Option (Right to Buy)Derivative14,058May 14, 2026

Activity

InsidersInstitutions
This person's insider trades (Form 4), across every company.
DateActionCompanyValueShares ΔPosition afterImpact
Jun 18, 2026GrantCRNX
Crinetics Pharmaceuticals, Inc.
Common Stock
$0+6K
+25.95%
28,761
0.03% of shares
low
Jun 9, 2026GrantATRA
Atara Biotherapeutics, Inc.
Common Stock
$0+12K
+65.98%
30,188
0.30% of shares
low
May 14, 2026GrantRARE
Ultragenyx Pharmaceutical Inc.
Common Stock
$0+8K
+29.87%
33,696
0.03% of shares
low
Jun 18, 2026GrantCRNX
Crinetics Pharmaceuticals, Inc.
Stock Option (Right to Buy)
+10K
9,730
<0.01% of shares
low
May 27, 2026GrantNMRA
Neumora Therapeutics, Inc.
Stock Option (Right to Buy)
+80K
80,000
0.04% of shares
low
May 14, 2026GrantRARE
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
+14K
14,058
0.01% of shares
low